Fibrinolytic therapy on renal protection in IgA nephropathy patients：a retrospective cohort study
10.3969/j.issn.1006-5725.2014.09.019
- VernacularTitle:促纤溶治疗对IgA肾病患者肾脏保护的回顾性队列研究
- Author:
Ming FANG
;
Hongli LIN
;
Hua XIE
;
Jilin CHEN
;
Yanling SUN
;
Panpan LIU
- Publication Type:Journal Article
- Keywords:
IgA nephropathy;
Urokinase;
Fibrinogenase
- From:
The Journal of Practical Medicine
2014;(9):1405-1407
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the protective effect of fibrinolytic therapy on renal function in patients with IgA nephropathy. Methods The clinical data of 84 patients with idiopathic IgA nephropathy were analyzed in a retrospective cohort study. According to different drugs of fibrinolytic therapy, the patients were divided into three groups including control group(n=23), urokinase group (n=32) and fibrinogenase group (n=29). Twenty-four-hour urine protein excretion, serum albumin, estimated glomerular filtration rate (eGFR), prothrombin time and fibrinogen level between the three groups after 6-month and 1-year treatments were compared. Results Compared to the group before treatment, the urine protein excretions were decreased in all 3 groups with 6-month and 1-year treatments (P<0.01). The urine protein excretion in the urokinase group with 6-month and 1-year treatments were lower than that in the control group (P<0.01). The urine protein excretion in the fibrinogenase group with 1-year treatment were lower that in the control group (P<0.05). After 1-year treatment, the eGFR in urokinase group was significantly increased compared with the control group (P<0.05). Conclusion Fibrinolytic therapy can decrease the 24-hour urine protein excretion and improve the renal fuction in those patients with idiopathic IgA nephropathy independent of glucocorticoids and immunosuppressive agents.
